Gluconex OD

Gliclazide

NIDDM (type 2) in adults in association w/ dietary measures & w/ exercise, when these measures alone are not sufficient.

Adult & elderly Initially 30 mg daily, may be used for maintenance treatment if blood glucose is effectively controlled. May be increased to 60 mg, 90 mg or 120 mg daily, in successive steps if blood glucose is not adequately controlled. Interval between each dose increment should be at least 1 mth. Max: 120 mg daily. Switching from another oral antidiabetic agent to gliclazide 60 mg 60 mg can be used to replace other oral antidiabetic agents. Patient at risk of hypoglycemia Initially min of 30 mg daily.

Should be taken with food: May be divided along the score-line. Do not crush/chew.

Hypersensitivity to gliclazide or other sulfonylurea, sulfonamides. Type 1 diabetes; diabetic pre-coma & coma, diabetic ketoacidosis. Treatment w/ miconazole. Severe renal or hepatic insufficiency. Lactation.

Undernourished or malnourished; severe or poorly compensated endocrine disorders eg, hypopituitarism, hypothyroidism, adrenocorticotropic insufficiency; w/drawal of prolonged &/or high dose corticosteroid therapy; severe vascular disease eg, severe CHD, severe carotid impairment, diffuse vascular disease. Risk of hypoglycemia. May affect blood glucose control w/ St. John's wort, fever, trauma, infection or surgical intervention. Consider adequate dose adjustment & dietary compliance before classifying patient as secondary failure. Careful monitoring of blood glucose in concomitant use w/ fluoroquinolone. G6PD deficiency. Not to be administered to patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Renal & hepatic insufficiency. Avoid use during pregnancy. Childn.

Hypoglycemia; sweating, clammy skin, anxiety, tachycardia, HTN, palpitations, angina pectoris & cardiac arrhythmia. GI disturbances including abdominal pain, nausea, vomiting, dyspepsia, diarrhea, & constipation.

Increased hypoglycemic effect w/ possible onset of hypoglycemia symptoms or even coma w/ miconazole. Increased hypoglycemic effect by displaces binding to plasma proteins &/or reduces elimination w/ phenylbutazone. Increased hypoglycemic reaction w/ alcohol or medicinal products containing alcohol. Potentiation of blood glucose lowering effect & hypoglycemia w/ other antidiabetic agents (insulins, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists), β-blockers, fluconazole, ACE inhibitors (captopril, enalapril), H₂-receptor antagonists, MAOIs, sulfonamides, clarithromycin & NSAIDs. Increased blood glucose levels & diabetogenic effect of danazol. Increased blood glucose levels w/ high doses of chlorpromazine. Increased blood glucose levels w/ possible ketosis w/ glucocorticoids (systemic & local route). Increased blood glucose levels due to β₂ agonist effects w/ IV ritodrine, salbutamol, terbutaline. Decreased exposure w/ St. John's wort. Risk of dysglycemia w/ fluoroquinolones. May lead to potentiation of anticoagulation w/ warfarin.

Antidiabetic Agents

A10BB09 - gliclazide ; Belongs to the class of sulfonylureas. Used in the treatment of diabetes.

Rx